发明名称 |
PEGYLATED TISSUE KALLIKREIN, AND PREPARATION METHOD THEREFOR AND USES THEREOF |
摘要 |
The present invention relates to polyethylene glycol (PEG) modified protein drugs, and a PEGylated tissue kallikrein, a preparation method and use thereof are disclosed. The tissue kallikrein has a sequence as shown in SEQ ID No. 1 or SEQ ID No. 2, and the tissue kallikrein may be natural or recombinant. The PEG has a molecular weight of 20 to 40 kDa, and is conjugated to the N-terminal primary amino of the tissue kallikrein. In addition to the advantages of significantly extended half-life, significantly reduced immunogenicity and stable and uniform structure, the biological activity of the PEGylated KLK1 provided in the present invention is improved to a higher extent, which is more significant in the treatment of cerebral apoplexy and diabetic nephropathy in particular. |
申请公布号 |
US2017049864(A1) |
申请公布日期 |
2017.02.23 |
申请号 |
US201415109364 |
申请日期 |
2014.01.09 |
申请人 |
ZONHON BIOPHARMA INSTITUTE INC. ;GENSUN INSTITUTE OF BIOMEDICINE CO.,LTD. |
发明人 |
MA Bruce Yong;WANG Jun;QIU Jing;WU Dinglong;XU Chunlin;CHEN Chen;WANG Yaofang |
分类号 |
A61K38/48;C12N9/64;A61K47/48 |
主分类号 |
A61K38/48 |
代理机构 |
|
代理人 |
|
主权项 |
1. A PEGylated tissue kallikrein, wherein the polyethylene glycol has a molecular weight of 20 to 40 kDa, and is conjugated to the-N-terminal primary amino of the tissue kallikrein. |
地址 |
Changzhou, Jiangsu CN |